Table 3 Response to second-line chemotherapy.
From: Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma
LCNEC | SCLC | P value | |
|---|---|---|---|
All | |||
Response, n (%) | |||
CR | 0 (0.0) | 5 (1.2) | 0.002 |
PR | 3 (7.7) | 150 (34.8) | |
SD | 18 (46.2) | 135 (31.3) | |
PD | 13 (33.3) | 114 (26.5) | |
Not evaluate | 5 (12.8) | 27 (6.3) | |
Overall response rate (%) | 7.7 (95% CI 1.6–20.9) | 36.0 (95% CI 31.4–40.7) | < 0.001 |
Patients receiving amrubicin monotherapy | |||
Response, n (%) | |||
CR | 0 (0.0) | 1 (0.5) | 0.002 |
PR | 2 (8.3) | 63 (30.3) | |
SD | 11 (45.8) | 66 (31.7) | |
PD | 9 (37.5) | 66 (31.7) | |
Not evaluate | 2 (8.3) | 12 (5.8) | |
Overall response rate (%) | 8.3 (95% CI 1.0–27.0) | 30.8 (95% CI 24.6–37.5) | 0.029 |
